{"id":"W2808209724","doi":"10.1136/annrheumdis-2018-eular.2140","title":"OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Enthesitis; Internal medicine; Placebo; Clinical endpoint; Golimumab; Synovitis; Gastroenterology; Arthritis; Surgery; Rheumatoid arthritis; Randomized controlled trial; Etanercept; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806672,0.001050707,0.002399071,0.0002849156,0.0003366197,0.001186943,0.000576581,0.001269288,0.002283754],"category_scores_gemma":[0.001135028,0.0004035,0.002282266,0.000349356,0.000773267,0.0008559349,0.000258835,0.003083207,0.0007313651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005388539,"about_ca_system_score_gemma":0.0008426853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006413415,"about_ca_topic_score_gemma":0.001496017,"domain_scores_codex":[0.9994316,0.0002240943,0.0000426614,0.00009497848,0.00008430202,0.0001223747],"domain_scores_gemma":[0.9992687,0.0002118912,0.0001416522,0.00005684751,0.00006583493,0.0002550919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7495178,0.01554723,0.006005332,0.001844102,0.005194058,0.0003456209,0.0002271528,0.001709851,0.02251546,0.0002573642,0.005598135,0.1912379],"study_design_scores_gemma":[0.7362533,0.2283982,0.02346529,0.0001305328,0.003095256,0.0005166396,0.00009747993,0.001367644,0.002944259,0.0003938616,0.003264408,0.00007326746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799436,0.01429986,0.0004739061,0.0008140791,0.0002457076,0.0006080222,0.001000413,0.0001551659,0.002459211],"genre_scores_gemma":[0.9885538,0.005138285,0.0009012707,0.001371431,0.0002940493,0.0005165924,0.001434481,0.00003403832,0.001756138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002399071,"threshold_uncertainty_score":0.009554744,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01758291275985717,"score_gpt":0.26635962034093,"score_spread":0.2487767075810728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}